

Cite this: *Chem. Sci.*, 2021, 12, 7561

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 22nd February 2021  
Accepted 24th April 2021

DOI: 10.1039/d1sc01029h

rsc.li/chemical-science

# Enantioselective Michael addition to vinyl phosphonates *via* hydrogen bond-enhanced halogen bond catalysis†

Mikk Kaasik, Jevgenija Martõnova, Kristin Erkman, Andrus Metsala, Ivar Järving and Tõnis Kanger \*

An asymmetric Michael addition of malononitrile to vinyl phosphonates was accomplished by hydrogen bond-enhanced bifunctional halogen bond (XB) catalysis. NMR titration experiments were used to demonstrate that halogen bonding, with the support of hydrogen-bonding, played a key role in the activation of the Michael acceptors through the phosphonate group. This is the first example of the use of XBs for the activation of organophosphorus compounds in synthesis. In addition, the iodo-perfluorophenyl group proved to be a better directing unit than different iodo- and nitro-substituted phenyl groups. The developed approach afforded products with up to excellent yields and diastereoselectivities and up to good enantioselectivities.

## Introduction

Halogen bonds (XBs), noncovalent interactions between electrophilic halogen atoms and Lewis bases,<sup>1</sup> are exploited in areas ranging from crystal engineering to catalysis.<sup>2</sup> The use of XBs in catalysis was first implemented by C. Bolm in 2008 for the reduction of quinolines.<sup>3</sup> Since then several studies have demonstrated the viability of XBs to achieve catalysis.<sup>4</sup> Notably, XBs have been used for the activation of imines in Mannich<sup>5</sup> and aza-Diels–Alder reactions,<sup>6</sup> for the activation of haloalkanes in halogen abstraction reactions,<sup>7</sup> and for the activation of carbonyl compounds in Diels–Alder,<sup>8</sup> Michael<sup>9</sup> and Nazarov reactions.<sup>10</sup> In addition, XBs have been used to activate other substrate classes, such as silyl halides,<sup>11</sup> thioamides<sup>12</sup> and the  $\pi$ -system of indoles.<sup>13</sup> Yet there are no examples of the activation of phosphorus compounds by XBs. This is surprising as XBs to phosphine oxides, phosphonates and phosphates have received attention in several solution studies.<sup>14</sup> Thus, organophosphorus compounds should be suitable substrates for XB catalysis.

Phosphorus compounds are an important class of molecules in organic synthesis both as valuable reagents and end targets.<sup>15</sup> More specifically, (chiral) organophosphonates and their phosphonic acid derivatives can be used in the much-acclaimed Horner–Wadsworth–Emmons reaction<sup>16</sup> and are also valuable

biomolecules.<sup>17</sup> Therefore, the asymmetric synthesis of organophosphonates has received significant attention over the years.<sup>18</sup> In several instances this has been successfully achieved through the use of well-developed asymmetric hydrogen-bond catalysis, which can be compared to the less explored XB catalysis. The two major advantages of XBs compared to HBs are their high directionality,<sup>19</sup> due to the formation of the XB at the elongation of the covalent bond to the halogen atom, and their high degree of variability. Namely, there is a choice among XB donor atoms, which can be ranked by the increase in their donor ability in the order of Cl < Br < I, corresponding to the increase in the polarisability of the halogen atom.<sup>20</sup> Although several examples can be found for the use of XBs in asymmetric synthesis, the deliberate use of XBs for catalytic purposes is still in its infancy.<sup>4e</sup> Notably, in 2018 the Arai group used a bifunctional alkaloid-based XB catalyst to carry out an asymmetric Mannich reaction,<sup>5a</sup> in 2020 the Huber group carried out the first solely XB-catalysed asymmetric reaction using the Mukaiyama-aldol reaction as a model<sup>21</sup> and in 2021 the Mancheño group demonstrated that a neutral tetrakis-iodo-triazole can be used as an asymmetric XB catalyst in the Reissert-type dearomatization of quinolone.<sup>22</sup>

We envisioned that the bifunctional alkaloid-based XB catalyst could be used to activate vinyl phosphonates in a Michael reaction with a nucleophile. Achieving this would both expand the chemical space of asymmetric XB catalysis and that of optically active phosphorus chemistry. We were also curious to see what influence the modification of the electronic properties and substitution pattern of the XB donor motif of the catalyst would have on the outcome of the reaction. So far, perfluorinated<sup>3,5,7b</sup> and azolium-type<sup>6a,7d,8a,13,21</sup> XB donor fragments have commonly been used in XB catalysts.

Department of Chemistry and Biotechnology, Tallinn University of Technology, Akadeemia tee 15, 12618 Tallinn, Estonia. E-mail: tonis.kanger@taltech.ee

† Electronic supplementary information (ESI) available: Solvent screening, experimental procedures, titration experiments, computational information, crystallographic information, and copies of NMR spectra and HPLC chromatograms. CCDC 2063122. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d1sc01029h



## Results and discussion

Initial experiments involving vinyl phosphonate **1a** and malononitrile **2** (Scheme 1) revealed that no reaction occurred in two days at RT in DCM (Table 1, entry 1). Gratifyingly, alkaloid-based XB catalysts facilitated the reaction, resulting in the formation of enantioenriched product **3a**. Quinidine- and dihydroquinine-derived catalysts **A** and **B** provided product **3a** in similar quantities and enantioenrichment levels (Table 1, entries 2 and 3). As expected, the enantioselectivity was opposite, because the catalysts were derived from pseudo-enantiomeric alkaloids (although in addition to this difference, the vinyl group connected to the quinuclidine fragment had been reduced in catalyst **B**). It was also observed that a side reaction resulting in compounds **4a** and **5** took place that reduced the yield of the product. To hinder this, catalyst loading was dropped to 10 mol% for the following experiments. In addition, 1,3,5-trimethoxybenzene ((MeO)<sub>3</sub>C<sub>6</sub>H<sub>3</sub>) was used as a quantitative internal standard to determine the distribution of starting materials and products in the reaction mixture by <sup>1</sup>H NMR spectroscopy. Cinchonidine-derived catalyst **C** performed much more sluggishly compared to catalysts **B**, providing product **3a** in lower conversion and enantioselectivity (Table 1, compare entries 4 and 5). In all cases, similar levels of moderate diastereoselectivity were observed. It was decided to continue with dihydroquinine-derived catalyst **B** due to its superiority in enhancing the rate of the reaction compared to **A**.

Next, an extensive solvent screening was conducted (for full details, see the ESI<sup>†</sup>), which revealed that the reaction performed well in apolar aprotic solvents, as would be expected of noncovalent catalysis. While the solvent influenced the reactivity and enantioselectivity significantly, the diastereoselectivity was not greatly affected. For further optimisation experiments, toluene was chosen as the solvent (Table 2, entry 1). During the last stage of optimisation, other reaction conditions were varied. The reaction slowed down when run under

Table 1 Initial results of the Michael reaction<sup>a</sup>


Entry	Catalyst	Time (h)	NMR yield of <b>3a</b> <sup>b</sup> (%)	d.r. <sup>c</sup>	ee <sup>d</sup> (%)
1	—	48	NR	ND	ND
2	<b>A</b>	48	89	85 : 15	−39/−40
3	<b>B</b>	22	84	87 : 13	40/43
4	<b>C</b> <sup>e</sup>	24	48	77 : 23	26/28
5	<b>B</b> <sup>e</sup>	24	86	85 : 15	45/46

<sup>a</sup> Unless otherwise noted, all reactions were carried out with 0.1 mmol of **1a**, 0.2 mmol of **2**, and 0.02 mmol of catalyst in 0.2 mL of DCM at RT; NR – no reaction, ND – not determined. <sup>b</sup> Relative amount of **3a** compared to the total amount of **1a**, **3a** and **5**; determined from the reaction mixture by <sup>1</sup>H NMR spectroscopy. <sup>c</sup> Determined from the reaction mixture by <sup>1</sup>H NMR spectroscopy. <sup>d</sup> Determined by HPLC analysis on a chiral stationary phase. <sup>e</sup> 10 mol% of catalyst instead of 20 mol% and (MeO)<sub>3</sub>C<sub>6</sub>H<sub>3</sub> was used as an internal standard.

Table 2 Optimisation of the reaction conditions<sup>a</sup>

Entry	T (°C)	C (M)	<b>B</b>		Conv. <sup>b</sup> (%)	5 <sup>c</sup> (%)	ee <sup>d</sup> (%)
			(mol%)	Time (h)			
1	RT	0.5	10	16	100	20	64/66
2	RT	0.1	10	39	87	7	76/77
3	RT	0.1	7.5	48	94	10	76/76
4	RT	0.1	5	48	76	5	79/76
5	40	0.1	5	48	100	25	76/73
6	0	0.1	10	48	81	0	79/81
7	0	0.2	10	48	97	2	76/76
8	−20	0.2	10	72	86	0	79/78

<sup>a</sup> Unless otherwise noted, all reactions were carried out with 0.1 mmol of **1a**, 0.2 mmol of **2**, and 0.05 mmol of (MeO)<sub>3</sub>C<sub>6</sub>H<sub>3</sub> in toluene; d.r. was determined from the reaction mixture by <sup>1</sup>H NMR spectroscopy and varied between 81 : 19 to 87 : 13; for full details see the ESI. <sup>b</sup> Conversion depicts the amount of reacted **1a** based on <sup>1</sup>H qNMR measurements using (MeO)<sub>3</sub>C<sub>6</sub>H<sub>3</sub> as an internal standard. Generally, the total amount of the formed **3a** and retro-Michael product **5** corresponded to the amount of **1a** depleted. <sup>c</sup> Describes the extent of product decomposition through the retro-Michael reaction determined by <sup>1</sup>H qNMR, using the methylene proton signal of triethyl phosphonoacetate **5**. <sup>d</sup> Determined by HPLC analysis on a chiral stationary phase.



Scheme 1 (a) Catalytic Michael reaction under study; (b) screened catalysts and decomposition products of **3a**.

more diluted conditions (Table 2, entry 2). Gratifyingly this also resulted in an increase in enantioselectivity. The reduction of catalyst loading under the diluted conditions had little effect on the enantioselectivity, yet resulted in a slower reaction (Table 2, entries 3 and 4). An increase of the temperature to 40 °C with a catalyst loading of 5 mol% resulted in full conversion within 2 days; however it also resulted in the increase of the retro-Michael process and did not have a positive influence on enantioselectivity (Table 2, entry 5). A decrease in temperature helped to somewhat improve the enantioselectivity at the expense of conversion (Table 2, entries 6 and 8). However, the retro-Michael process was significantly hindered at lower temperatures. As a compromise, the reaction was run at 0 °C, with 10 mol% catalyst loading and at a concentration of 0.2 M to hinder product decomposition (Table 2, entry 7). The product was formed in excellent NMR yield, with moderate




diastereoselectivity and acceptable enantioselectivities for both enantiomers. These conditions were then designated as optimal.

Throughout the studies, we were interested in changing the XB donor fragment of the catalyst. Usually, perfluorinated haloalkyl or -aryl groups are used for this purpose in neutral XB donors, which somewhat limits catalyst design. Yet, there are several other electron-withdrawing groups that can significantly increase the magnitude of the  $\sigma$ -hole on the halogen atom. To explore this, we synthesised catalysts **D–F** using benzoic acids with different iodo- and nitro-substitution patterns (Fig. 1). This would have also permitted us to explore the importance of the position of the iodine atom relative to the linker substituent. As references, the non-halogenated analogues **G–J** were also synthesised (Fig. 1). During the initial studies in DCM and under the optimised conditions in toluene, catalyst **B** always performed significantly better than its non-halogenated analogue **G**, in terms of both reactivity and selectivity (Fig. 1). These results demonstrate the positive effect of the iodine atom on catalyst activity and support XB involvement in the catalytic process. In contrast, catalysts **D–F**, containing nitro-substituted XB donor motifs, did not altogether demonstrate better performance compared to their non-halogenated analogues (Fig. 1, catalysts **H**, **I** and **J**). Moreover, all of the nitro-substituted catalysts were inferior to catalyst **B** in terms of enantioinduction, although some demonstrated better performance in terms of catalytic activity. Generally, the iodinated and non-halogenated catalysts resulted in products with similar diastereoselectivities, which overall varied between 79 : 21 and 89 : 11. Unfortunately, it was also not apparent whether the 1,2- or the 1,3- substitution pattern between the iodine atom and the linker site was more beneficial for enantioinduction and

catalytic activity. It can be reasoned that the steric influence of iodine in catalyst **B** results in higher levels of enantioselectivity. Catalysts **D**, **E** and **I** also contain a bulky substituent in the same position, yet these catalysts led to significantly lower levels of product enantioselectivity. Therefore, the steric influence of the large iodine atom alone cannot be used to explain the levels of enantioselectivity obtained with **B**. On the other hand, if as initially proposed the iodine acted as a directing group, then the XB donor ability of the iodine atom could provide an answer. Therefore, molecular electrostatic potentials were calculated (CAM-B3LYP functional,<sup>23</sup> DEF2TZVP basis set,<sup>24</sup> with the Gaussian 09 program,<sup>25</sup> solvent effects with PCM<sup>26</sup>) for the catalysts to determine the magnitude of the  $\sigma$ -hole on the iodine atom (Fig. 1a). The substitution pattern influenced the magnitude of the  $\sigma$ -hole considerably. In addition, the XB donor ability (represented by the  $\sigma$ -hole value) of these compounds seems to be dependent on the environment as catalyst **B** had the largest  $\sigma$ -hole in DCM, while catalyst **F** had the largest  $\sigma$ -hole in a vacuum. Unfortunately, no clear correlation between product selectivity and the XB donor ability of the catalyst can be drawn, although the calculations support the fact that catalyst **B** was the best XB donor in DCM.

Next, the scope and limitations of the method were explored under the optimised conditions. Aromatic substituents containing electron-withdrawing and electron-donating substituents were tolerated (Scheme 2, compare **3c** and **3d**), as well as variations in the position of different substituents either in the *ortho*, *meta* or *para* position (Scheme 2, compare **3e**, **3f** and **3g** to **3b**). The reaction could be carried out with halogenated (**3e–h**), sterically demanding naphthyl (**3k**), heteroaromatic (**3j**) and polyconjugated substrates (**3l**). It should be noted that the substitution pattern greatly affected the speed of the reaction.



a) DCM (0.5 M), 20 mol% catalyst, RT <sup>a</sup>																
	B, X = I <sup>b</sup>		G, X = H <sup>b</sup>		D, X = I <sup>b</sup>		H, X = H <sup>b</sup>		E, X = I <sup>b</sup>		I, X = H <sup>b</sup>		F, X = I <sup>c</sup>		J, X = H <sup>c</sup>	
Time	22 h	32 h	23 h	8 h	7 h	8 h	24 h	24 h <sup>d</sup>	24 h	8 h	14 h	20 h	21 h	25 h	18 h	23 h
NMR yield of <b>3a</b> <sup>d</sup>	88%	72%	78%	72%	84%	80%	81%	84%	84%	80%	14%	20%	21%	25%	18%	23%
ee <sup>e</sup>	40%/43%	10%/11%	12%/14%	20%/25%	22%/26%	14%/20%	21%/25%	18%/23%	22%	26%	14%	20%	21%	25%	18%	23%
$\sigma$ -hole <sup>f</sup>	DCM		vacuum		DCM		vacuum		DCM		vacuum		DCM		vacuum	
	0.0501	0.0450	0.0438	0.0411	0.0500	0.0448	0.0391	0.0464	0.0500	0.0448	0.0391	0.0464	0.0391	0.0464	0.0391	0.0464


b) toluene (0.2 M), 10 mol% catalyst, 0 °C <sup>a</sup>																
	B, X = I		G, X = H		D, X = I		H, X = H		E, X = I		I, X = H		F, X = I		J, X = H	
Time	48 h	48 h	48 h	45 h	42 h	18 h	42 h	41 h	42 h	18 h	42 h	41 h	42 h	41 h	42 h	41 h
NMR yield of <b>3a</b> <sup>d</sup>	95%	62%	87%	82%	92%	89%	86%	88%	92%	89%	86%	88%	86%	88%	86%	88%
ee <sup>e</sup>	76%/76%	40%/39%	40%/40%	31%/32%	43%/43%	40%/43%	41%/41%	40%/39%	43%/43%	40%/43%	41%/41%	40%/39%	41%/41%	40%/39%	41%/41%	40%/39%

<sup>a</sup> Unless otherwise noted, the reactions were carried out with 0.1 mmol of **1a**, 0.2 mmol of **2** and 0.05 mmol of (MeO)<sub>3</sub>C<sub>6</sub>H<sub>3</sub> with a catalyst in the stated solvent at the stated temperature. <sup>b</sup> (MeO)<sub>3</sub>C<sub>6</sub>H<sub>3</sub> not added initially, but prior to the end of the reaction. <sup>c</sup> 10 mol% of catalyst instead of 20 mol%. <sup>d</sup> NMR yield of **3a** based on <sup>1</sup>H qNMR measurements using (MeO)<sub>3</sub>C<sub>6</sub>H<sub>3</sub> as an internal standard. <sup>e</sup> Determined by HPLC analysis on a chiral stationary phase. <sup>f</sup> Energy values given in atomic units.

Fig. 1 Comparison of different XB/HB catalysts in (a) DCM and (b) toluene.







<sup>a</sup> **M** was not used as a single compound, but as a mixture of conformational isomers.

Scheme 3 Comparative experiments using (a) **6**, (b) **8** and (c) **1b** as Michael acceptors with different catalysts.

the iodine atom. Next, catalyst analogues were used in which the amidic hydrogen atom was omitted. Unfortunately, the *N*-methylated analogue **M** could not be isolated as a single compound and as a result the corresponding ester **L** was also synthesised. In both instances, the catalysts demonstrated poor catalytic activity and no enantioinduction. Therefore, the amidic hydrogen atom was also a critical design element of the catalyst.

To probe the participation of XBs in the reaction, <sup>1</sup>H NMR titration experiments in toluene-d<sub>8</sub> were carried out between the substrates of the reaction and catalyst analogues **9** to **13** of the XB donor motif (Table 3). In these achiral analogues the alkaloid moiety was omitted, although a possible hydrogen bond donor site in amides **9**, **10** and **13** was still present. Compounds **1b** and **9** formed complex [**1b-9**], with an association constant value of  $K_{\text{obs}} = 9.4 \text{ M}^{-1}$  (Table 3, entry 1), which was in the expected range based on the literature.<sup>14a</sup> Surprisingly, the non-halogenated analogue **10** also formed a relatively strong complex with compound **1b** (Table 3, entry 2), yet the corresponding association constant of  $K_{\text{obs}} = 2.5 \text{ M}^{-1}$  is about four times smaller. When the amidic hydrogen atom was omitted from the analogue, the interaction was more than an

Table 3 Association constants for XB donor and Michael reaction substrate pairs

Entry	XB acceptor	XB donor	$K_{\text{obs}}^a$ ( $\text{M}^{-1}$ )
1	<b>1b</b>	<b>9</b>	9.4
2	<b>1b</b>	<b>10</b>	2.5
3	<b>1b</b>	<b>11</b>	0.5
4	<b>1b</b>	<b>12</b>	0.4
5	<b>1b</b>	<b>13</b>	12.6
6 <sup>b</sup>	<b>1b</b>	<b>B</b>	3.4
7	<b>6</b>	<b>9</b>	1.3
8	<b>8</b>	<b>9</b>	14.0

<sup>a</sup> The  $K_{\text{obs}}$  was measured in toluene-d<sub>8</sub> and determined by fitting the <sup>1</sup>H NMR titration data of the *N*- or *O*-methyl protons to the 1 : 1 binding isotherm of BindFit.<sup>28</sup> The given  $K_{\text{obs}}$  is the calculated approximate mean value of two parallel experiments; in all cases the estimated standard errors fall below 10%. Full details are given in the ESI.

<sup>b</sup> Determined by fitting the <sup>19</sup>F NMR titration data of the fluorine atom *ortho* to the iodine atom to the 1 : 1 binding isotherm of BindFit.

order of magnitude weaker for analogues **11** and **12** (Table 3, compare entries 1, 3 and 4). Based on the control experiments, association constant values of  $K_{\text{obs}} = 0.5 \text{ M}^{-1}$  and  $K_{\text{obs}} = 0.4 \text{ M}^{-1}$  do not correspond to a sufficiently strong XB with the substrate to achieve a significant interaction with the substrate. Analogue **13** interacted strongly with substrate **1b**, which most likely was due to hydrogen-bonding between the two and reflects the increase of acidity of the amidic hydrogen atom in **13** by the perfluorophenyl group (Table 3, entry 5). Titration experiments were also carried out between catalyst **B** and compound **1b**. The association constant values of  $K_{\text{obs}} = 3.4 \text{ M}^{-1}$  signifies a favourable interaction between the two (Table 3, entry 6). In this instance, the change in the chemical shift of the fluorine atom *ortho* to the iodine atom was used as input for the calculation of the association constant value. The observed upfield shift upon the formation of complex [**1b-B**] is indicative of halogen bonding.<sup>29</sup>

Malonic ester-derived compound **6** and phosphonate **8** also formed complexes with XB donor **9**. The association constant corresponding to complex [**8-9**] (Table 3, entry 8) was larger than that for the [**1b-9**] complex. On the other hand, the association constant corresponding to complex [**6-9**] (Table 3, entry 7) was almost an order of magnitude smaller than that for the [**1b-9**] complex. Thus, the phosphonate group should be the



primary interaction site in the substrates and not the carbonyl group. This is also supported by the fact that when ethyl acetate was used as a solvent the reaction was not significantly hindered, as 87% conversion was reached in 24 hours and the ee of the product was 55% (this should be compared to entry 1 in Table 2; for further details, see the ESI†). The increase in the strength of the observable association constant in the series [6–9] < [1b–10] < [1b–9] < [1b–13] also aligns with the increase in reactivity in the corresponding catalytic reactions (comparison of results with catalysts B, G and K and reactions with substrates 1b and 6 in Scheme 3). The higher binding potential of the amide fragment also seems to correspond to increased levels of product enantioselectivity, although an iodine atom needs to be present for the best results. Therefore, the amide fragment acted as both a coordinating and an activating unit.

Based on these observations, we supposed that an XB is formed to substrate 1b and the interaction is strengthened by the participation of a hydrogen bond, either directly with the substrate or through hydrogen-bond-assisted halogen bonding. <sup>14b,30</sup> In the latter case, the 1,3-substitution pattern between the iodine atom and the linker substituent would not be favourable for catalytic purposes, which could be one reason for the poor performance of catalysts E and F (Fig. 1). To evaluate the interaction between catalyst B and substrate 1a, computations were performed (see the ESI† for details). These revealed that while an XB is formed to the oxygen atom of the phosphonate group, hydrogen-bonding to other acceptor sites in the substrate is not preferred. The calculated lowest energy conformers had an energy difference of 1.2 kcal mol<sup>-1</sup> (Fig. 2). It was observed that a stronger HB from the amide group to the iodine atom also resulted in the shortening of the XB to the oxygen atom of the phosphonate group. NCI analysis also confirmed the presence of hydrogen-bonding to the iodine atom (see Fig. S2 in the ESI† for details).

With the obtained knowledge, we now propose a catalytic cycle similar to the one proposed by the Arai group to describe the XB catalytic Mannich reaction.<sup>5</sup> First, malononitrile 2 is deprotonated and activated by the base in catalyst B (Fig. 3). Electrophile 1 is activated through an XB formed between the iodine atom in catalyst B and the oxygen atom of the phosphonate group in 1 (Fig. 3, [Y]). A hydrogen bond from the amide group of the catalyst to the iodine atom would enhance the XB to the phosphonate group (Fig. 3, middle). Direct activation of the phosphonate by hydrogen-bonding is also plausible and cannot be ruled out with the current experimental




Fig. 2 XB formation from B to the oxygen atom of the phosphonate group of 1a: (a) without HB enhancement and (b) with HB enhancement.




Fig. 3 Possible catalytic cycle for the enantioselective Michael reaction.

data. Next, a Michael reaction between 1 and 2 would result in the formation of intermediate [Z]. Protonation of this species leads to product 3. This in turn could be deprotonated by the catalyst, which could lead to a retro-Michael reaction through [Z']. Alternatively, it is possible that proton transfer in intermediate [Z] could also lead to intermediate [Z'], which in turn could be protonated to give product 3 or lead again to a retro-Michael reaction giving 4 and 5.

## Conclusions

A new asymmetric organocatalytic methodology was developed that utilises a hydrogen bond-enhanced bifunctional XB catalyst for the activation of vinyl phosphonates in a Michael reaction. This approach describes the first use of organophosphorus compounds as substrates in XB catalysis and furthermore expands the field of asymmetric XB catalysis. Comparative experiments with catalysts containing different XB donor units and their hydrogen-analogues confirmed the superiority of the iodoperfluoro group as an activating and enantioinducing unit. Furthermore, NMR titration experiments and computations demonstrated that this was primarily the result of halogen bonding, supported by hydrogen-bonding, with the phosphonate group.

## Author contributions

MK conceived the project. MK, KE conducted the synthesis and analysis. JM performed crystal analysis, IJ massspectrometric analysis, AM theoretical calculations. All authors contributed to the discussion. MK and TK wrote the manuscript with contributions from all authors. TK supervised the project.



## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This research was funded by the Estonian Ministry of Education and Research (grant no. PRG1031 and PRG399) and the Centre of Excellence in Molecular Cell Engineering (2014–2020.4.01.15-0013). We thank Dr Kadri Kriis for her help with the synthesis of catalyst A, Dr Aleksander-Mati Müürisepp for the IR spectra and Dr Marina Kudrjašova for the  $^{19}\text{F}$  NMR measurements.

## Notes and references

‡ However, it should be noted that the *Z*-isomers obtained were not as pure as the *E*-isomers.

§ The products were stable throughout purification by column chromatography on silica gel and subsequent solvent removal under reduced pressure. However, product decomposition was observed if left at temperatures above 50 °C for prolonged periods.

- C. G. R. Desiraju, P. Shing Ho, L. Kloo, A. C. Legon, R. Marquardt, P. Metrangolo, P. Politzer, G. Resnati and K. Rissanen, *Pure Appl. Chem.*, 2013, **85**, 1711–1713.
- For selected reviews, see: (a) L. C. Gilday, S. W. Robinson, T. A. Barendt, M. J. Langton, B. R. Mullaney and P. D. Beer, *Chem. Rev.*, 2015, **115**, 7118–7195; (b) G. Cavallo, P. Metrangolo, R. Milani, T. Pilati, A. Priimagi, G. Resnati and G. Terraneo, *Chem. Rev.*, 2016, **116**, 2478–2601; (c) H. Wang, W. Wang and W. J. Jin, *Chem. Rev.*, 2016, **116**, 5072–5104; (d) Á. M. Montaña, *ChemistrySelect*, 2017, **2**, 9094–9112; (e) *Halogen Bonding in Solution*, ed. S. Huber, Wiley, Weinheim, Germany, 2021.
- A. Bruckmann, M. A. Pena and C. Bolm, *Synlett*, 2008, 900–902.
- For recent reviews on the use of XBs in organocatalysis, see: (a) J. Bamberger, F. Ostler and O. G. Mancheño, *ChemCatChem*, 2019, **11**, 5198–5211; (b) R. L. Sutar and S. M. Huber, *ACS Catal.*, 2019, **9**, 9622–9639; (c) M. Breugst and J. J. Koenig, *Eur. J. Org. Chem.*, 2020, **2020**, 5473–5487; (d) H. Yang and M. W. Wong, *Molecules*, 2020, **25**, 1045; (e) M. Kaasik and T. Kanger, *Front. Chem.*, 2020, **8**, DOI: 10.3389/fchem.2020.599064.
- (a) S. Kuwano, T. Suzuki, Y. Hosaka and T. Arai, *Chem. Commun.*, 2018, **54**, 3847–3850; (b) S. Kuwano, Y. Nishida, T. Suzuki and T. Arai, *Adv. Synth. Catal.*, 2020, **362**, 1674–1678.
- (a) Y. Takeda, D. Hisakuni, C. H. Lin and S. Minakata, *Org. Lett.*, 2015, **17**, 318–321; (b) R. Haraguchi, S. Hoshino, M. Sakai, S. Tanazawa, Y. Morita, T. Komatsu and S. Fukuzawa, *Chem. Commun.*, 2018, **54**, 10320–10323; (c) M. Kaasik, A. Metsala, S. Kaabel, K. Kriis, I. Järving and T. Kanger, *J. Org. Chem.*, 2019, **84**, 4295–4303; (d) T. Suzuki, S. Kuwano and T. Arai, *Adv. Synth. Catal.*, 2020, **362**, 3208–3212.
- (a) S. M. Walter, F. Kniep, E. Herdtweck and S. M. Huber, *Angew. Chem., Int. Ed.*, 2011, **50**, 7187–7191; (b) F. Kniep, S. H. Jungbauer, Q. Zhang, S. M. Walter, S. Schindler, I. Schnapperelle, E. Herdtweck and S. M. Huber, *Angew. Chem., Int. Ed.*, 2013, **52**, 7028–7032; (c) L. Zong, X. Ban, C. W. Kee and C. H. Tan, *Angew. Chem., Int. Ed.*, 2014, **53**, 11849–11853; (d) S. H. Jungbauer and S. M. Huber, *J. Am. Chem. Soc.*, 2015, **137**, 12110–12120.
- (a) S. H. Jungbauer, S. M. Walter, S. Schindler, L. Rout, F. Kniep and S. M. Huber, *Chem. Commun.*, 2014, **50**, 6281–6284; (b) F. Heinen, E. Engelage, A. Dreger, R. Weiss and S. M. Huber, *Angew. Chem., Int. Ed.*, 2018, **57**, 3830–3833.
- (a) D. Von Der Heiden, E. Detmar, R. Kuchta and M. Breugst, *Synlett*, 2018, **29**, 1307–1313; (b) J. P. Gliese, S. H. Jungbauer and S. M. Huber, *Chem. Commun.*, 2017, **53**, 12052–12055; (c) R. A. Squitieri, K. P. Fitzpatrick, A. A. Jaworski and K. A. Scheidt, *Chem.–Eur. J.*, 2019, **25**, 10069–10073; (d) H. Zhang and P. H. Toy, *Adv. Synth. Catal.*, 2021, **363**, 215–221.
- (a) J. J. Koenig, T. Arndt, N. Gildemeister, J. M. Neudörfel and M. Breugst, *J. Org. Chem.*, 2019, **84**, 7587–7605; (b) A. Dreger, P. Wonner, E. Engelage, S. M. Walter, R. Stoll and S. M. Huber, *Chem. Commun.*, 2019, **55**, 8262–8265.
- M. Saito, N. Tsuji, Y. Kobayashi and Y. Takemoto, *Org. Lett.*, 2015, **17**, 3000–3003.
- A. Matsuzawa, S. Takeuchi and K. Sugita, *Chem.–Asian J.*, 2016, **11**, 2863–2866.
- S. Kuwano, T. Suzuki, M. Yamanaka, R. Tsutsumi and T. Arai, *Angew. Chem., Int. Ed.*, 2019, **58**, 10220–10224.
- (a) M. G. Sarwar, B. Dragisic, L. J. Salsberg, C. Gouliaras and M. S. Taylor, *J. Am. Chem. Soc.*, 2010, **132**, 1646–1653; (b) C. Laurence, J. Graton, M. Berthelot and M. J. El Ghomari, *Chem.–Eur. J.*, 2011, **17**, 10431–10444; (c) L. González, F. Zapata, A. Caballero, P. Molina, C. Ramírez De Arellano, I. Alkorta and J. Elguero, *Chem.–Eur. J.*, 2016, **22**, 7533–7544; (d) A. Borissov, J. Y. C. Lim, A. Brown, K. E. Christensen, A. L. Thompson, M. D. Smith and P. D. Beer, *Chem. Commun.*, 2017, **53**, 2483–2486; (e) A. S. Ostras, D. M. Ivanov, A. S. Novikov and P. M. Tolstoy, *Molecules*, 2020, **25**, 1406; (f) Y. P. Chang, T. Tang, J. R. Jagannathan, N. Hirbawi, S. Sun, J. Brown and A. K. Franz, *Org. Lett.*, 2020, **22**, 6647–6652.
- For selected reviews, see: (a) M. Mikolajczyk and P. Balczewski, in *New Asp. Phosphorus Chem. II*, ed. J.-P. Majoral, Springer, Berlin, Heidelberg, 2003, pp. 161–214; (b) *Phosphorus Ligands in Asymmetric Catalysis*, ed. A. Börner, Wiley-VCH, Weinheim, 2008; (c) O. I. Kolodiazny, V. P. Kukhar and A. O. Kolodiazna, *Tetrahedron: Asymmetry*, 2014, **25**, 865–922; (d) W. W. Metcalf and W. A. Van Der Donk, *Annu. Rev. Biochem.*, 2009, **78**, 65–94; (e) R. Morodo, P. Bianchi and J. C. M. Monbaliu, *Eur. J. Org. Chem.*, 2020, **2020**, 5236–5277.
- For selected reviews, see: (a) J. A. Bisceglia and L. R. Orelli, *Curr. Org. Chem.*, 2015, **19**, 744–775; (b) I. Janicki and P. Kielbasiński, *Adv. Synth. Catal.*, 2020, **362**, 2552–2596.
- For selected reviews, see: (a) R. Engel, *Chem. Rev.*, 1977, **77**, 349–367; (b) *Aminophosphonic and Aminophosphinic Acids: Chemistry and Biological Activity*, ed. V. P. Kukhar and H. R. Hudson, John Wiley & Sons, Chichester, 2000; (c) F. Orsini,



- G. Sello and M. Sisti, *Curr. Med. Chem.*, 2010, **17**, 264–289; (d) K. M. Heidel and C. S. Dowd, *Future Med. Chem.*, 2019, **11**, 1625–1643.
- 18 For selected reviews, see: (a) L. Albrecht, A. Albrecht, H. Krawczyk and K. A. Jørgensen, *Chem.–Eur. J.*, 2010, **16**, 28–48; (b) D. Zhao and R. Wang, *Chem. Soc. Rev.*, 2012, **41**, 2095–2108; (c) M. Dziegielewski, J. Pięta, E. Kamińska and Ł. Albrecht, *Eur. J. Org. Chem.*, 2015, **2015**, 677–702; (d) L. Chen, *Synthesis*, 2018, **50**, 440–469.
- 19 (a) K. Rissanen, *CrystEngComm*, 2008, **10**, 1107–1113; (b) P. Metrangolo, H. Neukirch, T. Pilati and G. Resnati, *Acc. Chem. Res.*, 2005, **38**, 386–395.
- 20 T. Clark, M. Hennemann, J. S. Murray and P. Politzer, *J. Mol. Model.*, 2007, **13**, 291–296.
- 21 R. L. Sutar, E. Engelage, R. Stoll and S. M. Huber, *Angew. Chem., Int. Ed.*, 2020, **59**, 6806–6810.
- 22 F. Ostler, D. G. Piekarski, T. Danelzik, M. S. Taylor and O. G. Mancheño, *Chem.–Eur. J.*, 2021, **27**, 2315–2320.
- 23 T. Yanai, D. P. Tew and N. C. Handy, *Chem. Phys. Lett.*, 2004, **393**, 51–57.
- 24 F. Weigend and R. Ahlrichs, *Phys. Chem. Chem. Phys.*, 2005, **7**, 3297–3305.
- 25 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery Jr, J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, *Gaussian 09, Revision D.01*, Gaussian, Inc., Wallingford CT, 2009.
- 26 J. Tomasi, B. Mennucci and R. Cammi, *Chem. Rev.*, 2005, **105**, 2999–3093.
- 27 T. Janecki, J. Kędzia and T. Wąsek, *Synthesis*, 2009, **2009**, 1227–1254.
- 28 (a) “Supramolecular.org – Binding Constant Calculators|Supramolecular” can be found at <http://supramolecular.org/>, 2021; (b) D. B. Hibbert and P. Thordarson, *Chem. Commun.*, 2016, **52**, 12792–12805.
- 29 D. von der Heiden, A. Vanderkooy and M. Erdélyi, *Coord. Chem. Rev.*, 2020, **407**, 213147.
- 30 D. A. Decato, A. M. S. Riel, J. H. May, V. S. Bryantsev and O. B. Berryman, *Angew. Chem., Int. Ed.*, 2021, **60**, 3685–3692.

